AC Immune SA (ACIU)
After hours:
| Previous close | 3.0300 |
| Open | 2.9900 |
| Bid | 2.9000 x 1200 |
| Ask | 3.0000 x 1000 |
| Day's range | 2.9400 - 3.0400 |
| 52-week range | 1.6800 - 3.8300 |
| Volume | |
| Avg. volume | 1,017,119 |
| Market cap | 248.088M |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8800 |
| Earnings date | 26 Oct 2023 - 30 Oct 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.26 |
ZacksAC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
ZacksAre Options Traders Betting on a Big Move in AC Immune (ACIU) Stock?
Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.
Globe NewswireAC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-perso
